Table 3.

Annualized mean healthcare costs of TKI based on treatment length in the 2nd L cohort

	Bosutinib (n = 60)	Dasatinib (n = 201)	Imatinib (n = 38)	Nilotinib (n = 142)	Ponatinib (n = 50)
Mean treatment length (years)	1.42	3.21	1.84	3.24	1.50
Annualized mean healthcare costs of treatment per patient (€)	34,800.8	39,277.6	10,622.0	35,404.0	51,559.3
Patients still in treatment at end of follow-up n (%)	32 (53.3%)	112 (55.7%)	18 (47.4%)	89 (62.7%)	25 (50%)
Follow-up, years (mean, SD)	2.1 (1.1)	3.2 (1.4)	2.7 (1.6)	3.3 (1.5)	2.1 (1.4)

The annualized healthcare cost of TKI treatment was estimated during the treatment-exposure period (calculated as costs for TKI prescription dispensed during a period from first to last prescription) and reproportioned for a 12-month period. Drug costs were evaluated using the INHS purchase price, i.e., costs after deduction of discount available for each LHU